Precision BioSciences (DTIL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Precision BioSciences

NasdaqCM•Healthcare•Biotechnology

$7.47+0.10(0.01%)Market closed

Market Cap

$172.46M

P/S

3.8x

P/B

3.8x

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Growth (17/25); weakest: Cash & Earnings Quality (6/25).

Profitability12/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 8.1x5y range 7.9x – 15.1x

P/S · 3.8x5y range 0.3x – 172.4x

Currently above its 20-quarter median.

P/B · 3.8x5y range 0.4x – 7.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $172.46M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $45.05M
Q. Revenue: $0
TTM EBITDA: $-34.42M
TTM Op. Income: $-36.40M
Q. Op. Income: $-19.16M
TTM Net Income: $-52.73M
Q. Net Income: $-32.65M
EPS: $-1.26
Shares Out.: $25.86M

$45.05M in TTM revenue grew 3473.0% YoY, reaching $0 last quarter. TTM EBITDA of $-34.42M and TTM operating income of $-36.40M show growth is flowing through to the bottom line. However, net income is negative at $52.73M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 3473% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -1916100000.0%
Net Margin: -3265200000.0%

Op. margin of -1916100000.0% is down 1915978461.1% YoY — costs are rising relative to revenue. Net margin at -3265200000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.8x
P/B Ratio: 3.8x

P/S of 3.8x and P/B of 3.8x. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $125.92M
Cash: $86.08M
Long-Term Debt: N/A
Book Value: $45.29M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-13.44M
TTM Free Cash Flow: $-51.94M
FCF Margin: -115.3%
FCF / Net Income: 1.0

TTM FCF of $-51.94M on $-13.44M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.